Investor Presentation
January 2023
medmix CONFIDENTIAL
The safe harbor statement under the
US private securities litigation reform act 1995
This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results or performance to differ materially from the statements made herein.
Note on Alternative Performance Measures (APM): all bridges from reported figures to APM can be found in the financial review of medmix' midyear report 2022 and all definitions of APM can be found in the APM section of medmix' annual report 2021
medmix CONFIDENTIAL
Overview
medmix CONFIDENTIAL
Medmix in 2021 | Global | |
footprint | ||
~2,000 | 15* | |
distribution | ||
Production, | ||
logistics and | ||
employees | sites | |
25% | ||
CHF | ||
457m | adj. EBITDA | >2.5bn |
revenue | margin | |
~900 | Products per year | |
active patents | ||
5 |
Note: * as at 31 December 2022
medmix CONFIDENTIAL
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Medmix Ltd. published this content on 12 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2023 11:39:03 UTC.